Malignant neoplasm of breast
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Over-expression of FSIP1 promotes breast cancer progression and confers resistance to docetaxel via MRP1 stabilization.
|
30814489 |
2019 |
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
The aim of this work was to assess the effect of long- and short-term incubation with daidzein, the second most abundant soy isoflavone and its metabolite equol on the expression and activity of P-glycoprotein, multidrug resistance-associated proteins 1 and 2 (MRP1 and MRP2) and BCRP in breast cancer cells.
|
29101532 |
2019 |
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
MDM2 drives TNBC circulating tumor cells (CTCs) in mice, but the context-dependent influences of MDM2 and MDMX on different subtypes of breast cancers expressing mtp53 have not been determined.
|
30642351 |
2019 |
Malignant neoplasm of breast
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Genes encoding proteins that have key functions in the DNA damage response, such as p53 and its inhibitors MDM2 and MDMX, are most likely candidates to harbor allelic variants that influence breast cancer susceptibility.
|
30956778 |
2019 |
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
This underscores the need for combinatorial approaches with focus on PXR antagonism to improve drug effectiveness in hepatocellular carcinoma.<b>Abbreviations:</b> HCC: Hepatocellular Carcinoma; FDA: Food and Drug Administration; TGF-β: Transforming growth factor-β; PXR: Pregnane X receptor; CAR: Constitutive androstane receptor; P-gp/ABCB1: P-glycoproteins/ATP-binding cassette transporter subfamily B member 1; MRP1/ABCC1 and MRP2/ABCC2: Multidrug-resistance associated proteins; BCRP/ABCG2: Breast cancer resistant protein; DMEs: Drug-metabolizing enzymes; CFDA: 5,6-carboxyfluorescein diacetate; ETS1: Transcription factor E26 transformation specific sequence 1.
|
31739702 |
2019 |
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
Correlations of MRP1 gene with serum TGF-β1 and IL-8 in breast cancer patients during chemotherapy.
|
30570851 |
2019 |
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
Contemplations, using the available literature, suggest that disrupting the stability and/or function of MDMX protein (and its downstream targets), in the context of mtp53 expressing BCs, might be beneficial for patient survival.
|
31489110 |
2019 |
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
The results showed that Que could increase intracellular accumulation of Dox in breast cancer cells through down-regulating the expression of efflux ABC transporters including P-gp, BCRP and MRP1, which can effectively eliminate cancerous cells including breast cancer stem cells (BCSCs), thereby potentiating the anti-tumor effect of Dox.
|
29475141 |
2018 |
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
Mir-1307 regulates cisplatin resistance by targeting Mdm4 in breast cancer expressing wild type P53.
|
29697201 |
2018 |
Malignant neoplasm of breast
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
linc00518 expression increased nearly 2 fold and MRP1 level elevated about 2.5 fold in breast cancer tissues as compared to that in adjacent normal tissues.
|
30001527 |
2018 |
Malignant neoplasm of breast
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our findings proposed that the MDM4 rs1380576 C>G polymorphism was a protective factor for BC risk in our population.
|
29439926 |
2018 |
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
Expression of LRP Gene in Breast Cancer Patients Correlated with MRP1 as Two Independent Predictive Biomarkers in Breast Cancer
|
30486550 |
2018 |
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
The overexpression of ATP-binding cassette transporters (ABC transporters), mainly including permeability glycoproteins (P-gp), multidrug resistance (MDR)-related protein 1 (MRP1), and breast cancer resistance proteins (BCRP), is one of the main reasons for the development of MDR which directly leads to chemotherapy failure.
|
30197538 |
2018 |
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
MDM4 is a rational target for treating breast cancers with mutant p53.
|
28097652 |
2017 |
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
The role of MDM2 and MDM4 in breast cancer development and prevention.
|
28096293 |
2017 |
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
Even nontoxic dose of Tan IIA could also promote intracellular Dox accumulation of MCF-7 and MCF-7/dox cells through down-regulating the expression of efflux ABC transporters including P-gp, BCRP and MRP1, which can effectively eliminated cancerous cells including BCSCs, thereby enhancing the chemosensitivity of breast cancer.
|
29028589 |
2017 |
Malignant neoplasm of breast
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We report that the expression of MDM4 and MDM2 is elevated in primary human breast cancers of luminal A/B subtypes and associates with ERα-positive disease, independently of p53 mutation status.
|
26909605 |
2016 |
Malignant neoplasm of breast
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We conclude, MDM4 SNP34091 status to be associated with reduced risk of breast cancer, in particular in individuals carrying the MDM2 SNP309GG genotype, but not to be associated with either lung-, colon- or prostate cancer.
|
26471763 |
2015 |
Malignant neoplasm of breast
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Recently, a 4-nitrobenzofuroxan derivative, XI-006 (NSC207895) was shown to diminish MDM4 promoter activity in breast cancer cell lines.
|
26095524 |
2015 |
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
Based on our findings, we propose that Mdmx targeting is an attractive strategy for treating BrCas harboring wt p53.
|
26181202 |
2015 |
Malignant neoplasm of breast
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Here, we show that the EMT phenotype in multiple cellular models and in clinical prostate and breast cancer samples is associated with a decrease in MDM2 and increase in MDMX expression.
|
26416355 |
2015 |
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
Interaction between p53 mutation and a somatic HDMX biomarker better defines metastatic potential in breast cancer.
|
25649770 |
2015 |
Malignant neoplasm of breast
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Interestingly, we observed a combinational effect between MDM4 rs4245739 and P53 Arg72Pro variants in attenuating breast cancer risk, highlighting the importance of the P53 tumor suppressor pathway genes during malignant transformation.
|
23793604 |
2013 |
Malignant neoplasm of breast
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC).
|
23396606 |
2013 |
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
MRP1 but not MDR1 is associated with response to neoadjuvant chemotherapy in breast cancer patients.
|
23481629 |
2013 |